According to Janssen, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended that Zytiga (abiraterone acetate) plus prednisone when used in combination with androgen deprivation therapy (ADT) be approved in the European Union for early stage prostate cancer.
Early stage prostate cancer is defined as men who are newly diagnosed, at high-risk and have metastatic hormone-sensitive prostate cancer.
The current standard of care for these men is ADT alone.
The European Commission, which has the authority to approve or deny this new indication, will review the CHMP’s recommendation.
Joel T. Nowak, MA, MSW wrote this Post. Joel is the CEO/Executive Director of Cancer ABCs. He is a Cancer Thriver diagnosed with five primary cancers - Thyroid, Metastatic Prostate, Renal, Melanoma, and Appendiceal Cancer a rare cancer.
